PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

PETACH TIKVA, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX₁₀₀ will be highlighted in a podium presentation at the European Society for Coloproctology (ESCP) Scientific Conference to be held on September 21-23, 2022, in Dublin, Ireland.

European Society for Coloproctology Scientific Conference:

PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data and animal study data for D-PLEX₁₀₀ in surgical trauma injuries will be highlighted in a podium presentation at the 2022 Military Health System Research Symposium (MHSRS) being held on September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida.

The 2022 Military Health System Research Symposium:

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide an update on business operations.

To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

For those not planning to ask management a question, the Company recommends listening via the webcast using the link here.

Conference Call Dial-In & Webcast Information:

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader (“KOL”) webinar on the cost of managing surgical site infections (“SSIs”) on Thursday, June 23, 2022, at 10:00 AM Eastern Time.

The webinar will feature presentations from KOLs Kyle Cologne, M.D., Los Angeles County General – USC Medical Center, who will provide a general-hospital perspective on the cost of managing SSIs, and Elliot Goodman, M.D., Mount Sinai Health System, who will discuss the impact SSIs have on quality measures and performance from an integrated delivery network (IDN) perspective.

The PolyPid leadership team will provide a corporate update, including a discussion on the timing of the topline results following the recent completion of patient enrollment in the SHIELD I Phase 3 study of D-PLEX₁₀₀ for the prevention of SSIs in abdominal surgery.

A question and answer session will follow. To register for the event, please click here.

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is being held in New York City, on June 15-16, 2022.

Investors interested in meeting with PolyPid during the conference should contact their JMP representative.

Conference Call Dial-In & Webcast Information:

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this year’s summit is From Hope to Product – The Brilliant Prospect in Nanomedicine and Related Fields.

Dr. Noam Emanuel, Chief Scientific Officer of PolyPid, will present the abstract, ‘From Bench to Bedside: D-PLEX₁₀₀ Limits AMR Occurrence in Randomized Double-Blind Phase 2 Trial in Colorectal Surgery Patients,’ demonstrating D-PLEX₁₀₀ as a safe and effective surgical site infection prevention agent without affecting the incidence of postoperative colonization by multi drug resistant organisms. Dr. Emanuel’s presentation will be available on https://www.polypid.com/ following the summit.

PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting, being held on April 23-26, 2022 in Dallas, TX.

The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,’ evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be available on https://www.polypid.com/ following the presentation.